Skip to main content
SpringerLink
Log in

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as infections, sensitization impeding transplantation, and secondary iron overload. However, even in the initial studies, untoward effects were noted in patients receiving ESAs, including worsening hypertension, seizures, and dialysis access clotting. Later, increased mortality, malignancy progression and even stroke were reported in renal patients. This review focuses on the safety issues of ESAs in CKD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bright R. Cases and observations: illustrative of renal disease accompanied by the secretion of albuminous urine. Guys Hosp Rep. 1836;1:338.

    Google Scholar 

  2. KDOQI National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):S11–145.

    Google Scholar 

  3. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature. 1957;179:633–4.

    Article  CAS  PubMed  Google Scholar 

  4. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252:5558–64.

    CAS  PubMed  Google Scholar 

  5. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.

    Article  CAS  PubMed  Google Scholar 

  6. van Rijt WG, van Goor H, Ploeg RJ. LeuveninkHGD. Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events. Transplant Intl. 2014;27:241–248.

  7. Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49:749–54.

    Article  CAS  PubMed  Google Scholar 

  8. Akizawa T, Koshikawa S, Takaku F, Urabe A, Akiyama N, Mimura N, et al. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan. Int J Artif Organs. 1988;11(5):343–50.

    CAS  PubMed  Google Scholar 

  9. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4(2):470–80.

    Article  CAS  PubMed  Google Scholar 

  10. Schulz EG, Neumann CL, Menne J, Schettler V, Mackenbrock C, Popov AF, et al. An erythropoietin gene polymorphism in the hypoxia-responsive element at position 3434 is possibly associated with hypertension. Kidney Blood Press Res. 2012;35(2):71–6.

    Article  CAS  PubMed  Google Scholar 

  11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, TREAT investigators, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.

    Article  PubMed  Google Scholar 

  12. Inrig JK, Sapp S, Barnhart H, Patel UD, et al. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant. 2012;27(9):3606–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med. 2006;335:2071–84.

    Article  Google Scholar 

  14. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–8.

    Article  CAS  PubMed  Google Scholar 

  15. Del Vecchio L, Lusenti T, Del Rosso G, Malandra R, Balducci A, Losito A, Group For Arterial Hypertension of the Italian Society Of Nephrology. Prevalence of hypertension in a large cohort of Italian hemodialysis patients: results of a cross-sectional study. J Nephrol. 2013;26(4):745–54. doi:10.5301/jn.5000202 (Epub 2012 Oct 12).

  16. Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CFM, et al. Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One. 2013;8(12):e84848. doi:10.1371/journal.pone.0084848.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GFM. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12:CD010590. doi:10.1002/14651858.CD010590.pub2.

  18. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.

    Article  CAS  PubMed  Google Scholar 

  19. Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant. 1992;7:811–6.

    CAS  PubMed  Google Scholar 

  20. Viron B, Chamma F, Jaar B, Michel C, Mignon F. Thrombosis of angioaccess in haemodialysed patients treated with human recombinant erythropoietin. Nephrol Dial Transplant. 1997;12:368–70.

    Article  CAS  PubMed  Google Scholar 

  21. Vinhas J, Barreto C, Assunção J, Parreira L, Vaz A. Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease doesnot lower mortality and may increase cardiovascular risk: a meta-analysis. Nephron Clin Pract. 2012;121(3–4):c95–101.

    Article  CAS  PubMed  Google Scholar 

  22. Moody WE, Edwards NC, Chue CD, Ferro CJ, Townend JN. Arterial disease in chronic kidney disease. Heart. 2013;99(6):365–72.

    Article  CAS  PubMed  Google Scholar 

  23. Abraham PA, Opsahl JA, Keshaviah PR, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis. 1990;16:438–46.

    Article  CAS  PubMed  Google Scholar 

  24. Maurin N. Die Rolle der Thrombozyten bei Atherosklerose, Diabetes mellitus und chronischer Niereninsuffizienz. Med Klin (Munich). 2010;105(5):339–44.

    Article  CAS  Google Scholar 

  25. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610–5.

    Article  PubMed  Google Scholar 

  26. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med. 2006;335:2085–98.

    Article  Google Scholar 

  27. KDOQI Advisory Board Members. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530.

    Article  Google Scholar 

  28. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, TREAT Investigators, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011;124:2903–8.

    Article  CAS  PubMed  Google Scholar 

  29. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.

    Article  CAS  PubMed  Google Scholar 

  30. Zakai NA, Lange L, Longstreth WT Jr, O’Meara ES, Kelley JL, Fornage M, et al. Association of coagulation-related and inflammation-related genes and factor VIIc levels with stroke: the Cardiovascular Health Study. J Thromb Haemost. 2011;9(2):267–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Suttorp MM, Hoekstra T, Ocak G, van Diepen AT, Ott I, Mittelman M, et al Erythropoiesis‐stimulating agents and thrombotic events in dialysis patients. Thromb Res. 2014;134:1081–6.

  32. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61(1):44–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–75.

    Article  CAS  PubMed  Google Scholar 

  34. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20(12):1903–7.

    Article  CAS  PubMed  Google Scholar 

  35. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126(2):114–8.

    Article  CAS  PubMed  Google Scholar 

  36. Del Vecchio L, Locatelli F. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. Expert Opin Drug Saf. 2012;11(6):923–31.

    Article  PubMed  Google Scholar 

  37. Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a(HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8–17.

    Article  CAS  PubMed  Google Scholar 

  38. Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoietin stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–42.

    Article  CAS  PubMed  Google Scholar 

  40. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102:301–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2006;3:CD003407.

    PubMed  Google Scholar 

  42. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–14.

    Article  CAS  PubMed  Google Scholar 

  43. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011;125:55–67.

    Article  PubMed  Google Scholar 

  44. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005;97:489–98.

    Article  CAS  PubMed  Google Scholar 

  45. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1–220.

    Article  CAS  PubMed  Google Scholar 

  46. Seidenfeld J, Piper M, Bohlius J, Piper M, Schwarzer G, Sandercock J, et al. Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Rockville: Agency for Healthcare Research and Quality; 2006. http://effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf. Accesed 29 Jan 2016.

  47. Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ. 2009;180:E62–71.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006;28:801–31.

    Article  CAS  PubMed  Google Scholar 

  49. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.

    Article  CAS  PubMed  Google Scholar 

  50. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407. doi:10.1002/14651858.CD003407.pub5 (Review. PubMed PMID: 23235597).

  51. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer. 2008;99:14–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Li X, Yan Z, Kong D, et al. Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis. Chin J Cancer Res. 2014;26:268–76.

    PubMed  PubMed Central  Google Scholar 

  53. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27:2838–47.

    Article  CAS  PubMed  Google Scholar 

  54. Aapro M, Coiffier B, Dunst J, Osterborg A, Burger HU. Effect of treatment with epoetin beta on short-term mour progression and survival in anaemic patients with cancer: a meta-analysis. Br J Cancer. 2006;95:1467–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Grant MD, Piper M, Bohlius J, Tonia T, Robert N, Vats V, Bonnell C, et al. Epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: comparative effectiveness update. Comparative Effectiveness Review No. 113 (Prepared by the Blue Cross and Blue Shield Association Technology valuation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I) AHRQ Publication No. 13-EHC077-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2013. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accesed 20 July 2015.

  56. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005;23:6941–8.

    Article  CAS  PubMed  Google Scholar 

  57. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574–82.

    Article  CAS  PubMed  Google Scholar 

  58. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, et al. Erythropoietin and granulocytecolony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607–13.

    Article  PubMed  Google Scholar 

  59. Musto P, Villani O, Martorelli MC, Pietrantuono G, Guariglia R, Mansueto G, et al. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. Leuk Res. 2010;34:981–5.

    Article  CAS  PubMed  Google Scholar 

  60. FDA Briefing Document. Oncologic Drugs Advisory Committee. Continuing reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf. Accesed 20 July 2016.

  61. Debeljak N, Solár P, Sytkowski AJ. Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol. 2014;5:563. doi:10.3389/fimmu.2014.00563 (eCollection 2014. Review. PubMed PMID: 25426117; PubMed Central PMCID: PMC4227521).

  62. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011;80(3):288–94.

    Article  CAS  PubMed  Google Scholar 

  63. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Anaemia Working Group of European Renal Best Practice (ERBP), et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant. 2010;25(9):2846–50.

    Article  PubMed  Google Scholar 

  64. http://www.transcrip-partners.com/wp-content/uploads/2013/06/Improving-Global-Outcomes-KDIGO-guidelines-commentary-19-06-2013.pdf. Accesed 5 July 2015.

  65. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline foranemia in chronic kidney disease. Kidney Inter. Suppl.2012;2:279–335.

  66. Bellinghieri G, Condemi CG, Saitta S, Trifirò G, Gangemi S, Savica V, et al. Erythropoiesis-stimulating agents: dose and mortality risk. J Ren Nutr. 2015;25:164–8.

    Article  CAS  PubMed  Google Scholar 

  67. Fort J, Cuevas X, García F, Pérez-García R, Lladós F, Lozano J, Martín-Malo A, ANSWER study. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol Dial Transplant. 2010;25:2702–10.

    Article  CAS  PubMed  Google Scholar 

  68. Lau JH, Gangji AS, Rabbat CG, Brimble KS. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010;25:4002–9.

    Article  CAS  PubMed  Google Scholar 

  69. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–76.

    Article  CAS  PubMed  Google Scholar 

  71. Santos PR, Melo AD, Lima MM, Negreiros IM, Miranda JS, Pontes LS, et al. Mortality risk in hemodialysis patients according to anemia control and erythropoietin dosing. Hemodial Int. 2011;15(4):493–500.

    Article  PubMed  Google Scholar 

  72. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757–67.

    Article  CAS  PubMed  Google Scholar 

  73. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23–33.

    Article  PubMed  Google Scholar 

  74. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2001;4:CD003266.

    PubMed  Google Scholar 

  75. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005;3:CD003266.

    PubMed  Google Scholar 

  76. Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev. 2014;5:CD003895. doi:10.1002/14651858.CD003895.pub3.

  77. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439–46.

    Article  CAS  PubMed  Google Scholar 

  78. Strippoli GF, Manno C, Schena FP, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Cochrane Database Syst Rev. 2003;1:CD003967.

    PubMed  Google Scholar 

  79. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol. 2004;15(12):3154–65.

    Article  PubMed  Google Scholar 

  80. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006;4:CD003967.

    PubMed  Google Scholar 

  81. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med. 2009;169:1104–12.

    Article  CAS  PubMed  Google Scholar 

  82. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Association between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–91.

    Article  CAS  PubMed  Google Scholar 

  83. Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013;5(14):200. doi:10.1186/1471-2369-14-200 (PubMed PMID: 24066978; PubMed Central PMCID: PMC3849281).

    Article  Google Scholar 

  84. Singh AK: What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010;19:420–424.

  85. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modifyerythropoietic response. Clin J Am Soc Nephrol. 2010;5:576–81.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Fandrey J, Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood. 2003;81:617–23.

    Google Scholar 

  87. Dunn CJ, Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs. 1996;51(2):299–318.

    Article  CAS  PubMed  Google Scholar 

  88. Gassmann M, Heinicke K, Solitz J, Ogunshola OO. Nonerythroid functions of erythropoietin. Adv Exp Med Biol. 2003;543:323–30.

    Article  CAS  PubMed  Google Scholar 

  89. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol. 2007;2(6):1274–82.

    Article  CAS  PubMed  Google Scholar 

  90. Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF. Darbepoetin for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2014;3:CD009297. doi:10.1002/14651858.CD009297.pub2.

  91. Pérez-Ruixo JJ, Cucala-Ramos M, García-Gonzalo E, Del Val Romero B, Valveny N. Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. Br J Clin Pharmacol. 2013;75(1):15–25.

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Risk Institute, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain

    Nicolas Roberto Robles

  2. Unidad de Hipertensión Arterial, Hospital Infanta Cristina, Carretera de Portugal s/n, 06070, Badajoz, Spain

    Nicolas Roberto Robles

Authors
  1. Nicolas Roberto Robles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Roberto Robles.

Ethics declarations

Funding

There was no source of funding.

Conflicts of interest

Nicolas Roberto Robles declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Robles, N.R. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 36, 421–431 (2016). https://doi.org/10.1007/s40261-016-0378-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-016-0378-y

Keywords

Search

Navigation